3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other solid neoplasm
2
Conditions
Stomach Neoplasms
2
Solid Tumor
2
Meningioma
2
Carcinoma, Non-Small-Cell Lung
2
Small Cell Lung Carcinoma
1
Recurrence
1
Non-small Cell Lung Cancer Metastatic
1
Neurofibromatosis 2
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Estrogen Receptor Positive Breast Cancer
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
apatinib
3
vistusertib
2
olaparib
2
camrelizumab
2
atezolizumab
2
Ipilimumab
2
Everolimus
2
trametinib
1
toripalimab
1
tilsotolimod
1
tazemetostat
1
tazarotene
1
spartalizumab
1
seviteronel
1
sargramostim
1
sacituzumab govitecan
1
rucaparib
1
roniciclib
1
romiplostim
1
pyrotinib
1
phosphorylethanolamine
1
pemigatinib
1
pembrolizumab
1
pazopanib
1
palbociclib
1
niraparib
1
magrolimab
1
lenvatinib
1
irinotecan sucrosofate
1
famitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Solid Tumor
×
vistusertib
×
Clear all
NCT03166176
2019-05-20
TSC1/2_SC
Samsung Medical Center
Phase 2
Withdrawn
NCT03166904
2019-05-20
RICTOR_SC
Samsung Medical Center
Phase 2
Withdrawn